Evidence map›Paper›PMID 35782626›Full record

ArticleMolecular genetics and metabolism reports2022

Compound heterozygote variants: c.848A > G; p.Glu283Gly and c.890C > T; p.Ala297Val, of Isovaleric acid-CoA dehydrogenase

Anne Chun-Hui Tsai, Hsin-Ti Lin, Maxwell Chou, Jessica Bolen, Chelsea Zimmerman, Danielle DeMarzo, Yazmin Enchautegui-Colon

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics and metabolism reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anne Chun-Hui TsaiSection of Genetics, Department of Pediatrics, University of Oklahoma Health sciences Center, Oklahoma Children's Hospital, Oklahoma City, OK, United States of America.
Hsin-Ti LinSection of Genetics, Department of Pediatrics, University of Oklahoma Health sciences Center, Oklahoma Children's Hospital, Oklahoma City, OK, United States of America.
Maxwell ChouSection of Genetics, Department of Pediatrics, University of Oklahoma Health sciences Center, Oklahoma Children's Hospital, Oklahoma City, OK, United States of America.
Jessica BolenSection of Genetics, Department of Pediatrics, University of Oklahoma Health sciences Center, Oklahoma Children's Hospital, Oklahoma City, OK, United States of America.
Chelsea ZimmermanSection of Genetics, Department of Pediatrics, University of Oklahoma Health sciences Center, Oklahoma Children's Hospital, Oklahoma City, OK, United States of America.
Danielle DeMarzoSection of Genetics, Department of Pediatrics, University of Oklahoma Health sciences Center, Oklahoma Children's Hospital, Oklahoma City, OK, United States of America.
Yazmin Enchautegui-ColonSection of Genetics, Department of Pediatrics, University of Oklahoma Health sciences Center, Oklahoma Children's Hospital, Oklahoma City, OK, United States of America.
Children's Hospital of Oklahoma · USUniversity of Oklahoma · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the execution of expanded newborn screen (NBS) program nationwide, it is uncommon to see severe hyperammonemia associated with isovaleric acidemia (IVA). We present a seven-day-old boy with severe IVA complicated by hyperammonemia. This child was flagged by NBS at 4 days old, but confirmatory testing was delayed due to COVID19 pandemic and parental skepticism. His parents did not adhere to the leucine-restricted diet as recommended. On day 7, the patient presented to the ER with ammonia of 588 μg/dL. Ammonia subsequently rose to >1000 μg/dL. This child received carnitine, 1 dose of Ammonul (sodium benzoate and sodium phenylacetate), arginine, carglumic acid (Carbaglu) and CRRT. Plasma amino acid assay revealed a glutamine level of 256 μmol/L, which is below the lower limit of normal upon arrival to ER and PICU. The hyperammonemia was corrected in 15 h and with the continued use of carglumic acid for 3 days, there was no rebound of hyperammonemia. However, the patient suffered from bone marrow suppression associated with the organic acidemia and required frequent platelet transfusions, as well as G-CSF for neutropenia. The management of this patient provides supporting evidence of the many theoretic metabolic "facts" including why Ammonul is not helpful in organic acidemias.

Indexed as

AmmonulBone marrow suppressionCarglumic acidGranulocyte-colony stimulating factorHyperammonemiaIsovaleric acidemia

Identifiers

PMID35782626
PMCPMC9248227
OpenAlexW4221092190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.